EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Impact of Integrase Inhibitors on Cardiovascular Disease Events in People With Human Immunodeficiency Virus Starting Antiretroviral Therapy

Bernard Surial iD, Frédérique Chammartin, José Damas, Alexandra Calmy, David Haerry, Marcel Stöckle, Patrick Schmid, Enos Bernasconi, Christoph A Fux, Philip E Tarr, Huldrych F Günthard, Gilles Wandeler und 2 weitere

Clinical Infectious Diseases · 11.09.2023 · 77 (5) · 729-737

DOI: 10.1093/cid/ciad286 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 09.05.2023. Verfasst von Bernard Surial und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Anti-HIV Agents, Cardiovascular Diseases, HIV Infections, HIV Integrase Inhibitors. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: framework of the SHCS, Swiss National Science Foundation, SHCS research foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Integrase strand transfer inhibitors (INSTIs) have been associated with an increased risk for cardiovascular disease (CVD) events. We investigated the impact of starting INSTI-based antiretroviral therapy (ART) on CVD events among treatment-naïve people with human immunodeficiency virus using a target trial framework, which reduces the potential for confounding and selection bias.

Methods

We included Swiss HIV Cohort Study participants who were ART-naïve after May 2008, when INSTIs became available in Switzerland. Individuals were categorized according to their first ART regimen (INSTI vs other ART) and were followed from ART start until the first of CVD event (myocardial infarction, stroke, or invasive cardiovascular procedure), loss to follow-up, death, or last cohort visit. We calculated hazard ratios and risk differences using pooled logistic regression models with inverse probability of treatment and censoring weights.

Results

Of 5362 participants (median age 38 years, 21% women, 15% of African origin), 1837 (34.3%) started INSTI-based ART, and 3525 (65.7%) started other ART. Within 4.9 years (interquartile range, 2.4–7.4), 116 CVD events occurred. Starting INSTI-based ART was not associated with an increased risk for CVD events (adjusted hazard ratio, 0.80; 95% confidence interval [CI], .46–1.39). Adjusted risk differences between individuals who started INSTIs and those who started other ART were −0.17% (95% CI, −.37 to .19) after 1 year, −0.61% (−1.54 to 0.22) after 5 years, and −0.71% (−2.16 to 0.94) after 8 years.

Conclusions

In this target trial emulation, we found no difference in short- or long-term risk for CVD events between treatment-naïve people with human immunodeficiency virus who started INSTI-based ART and those on other ART.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsCardiovascular DiseasesHIV InfectionsHIV Integrase InhibitorsAdultFemaleHumansMaleCohort StudiesHIV

Stichwörter der Autor:innen

antiretroviral therapyintegrase strand transfer inhibitormyocardial infarctionstroketreatment-naïve

Substanzen

Anti-HIV AgentsHIV Integrase Inhibitors

Autor:innen und Institutionen

  • Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Division of Infectious Diseases, University Hospital of Lausanne, University of Lausanne, Lausanne, Switzerland.
  • Division of Infectious Diseases, Geneva University Hospital, University of Geneva, Geneva, Switzerland.
  • Chair Positive Council, Zurich, Switzerland.
  • Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, Basel, Switzerland.

ORCID-Profile: Bernard Surial

Förderung

  • framework of the SHCS
  • Swiss National Science Foundation
  • SHCS research foundation
  • 5 Swiss University Hospitals

Zitieren

APA

Surial, B., Chammartin, F., Damas, J., Calmy, A., Haerry, D., Stöckle, M., Schmid, P., Bernasconi, E., Fux, C. A., Tarr, P. E., Günthard, H. F., Wandeler, G., Rauch, A., & Swiss HIV Cohort Study (2023). Impact of Integrase Inhibitors on Cardiovascular Disease Events in People With Human Immunodeficiency Virus Starting Antiretroviral Therapy. Clinical Infectious Diseases, 77(5), 729-737. https://doi.org/10.1093/cid/ciad286

Vancouver

Surial B, Chammartin F, Damas J, Calmy A, Haerry D, Stöckle M, et al. Impact of Integrase Inhibitors on Cardiovascular Disease Events in People With Human Immunodeficiency Virus Starting Antiretroviral Therapy. Clinical Infectious Diseases. 2023;77(5):729-737. doi:10.1093/cid/ciad286

BibTeX
@article{Surial2023,
  author = {Surial, Bernard and Chammartin, Frédérique and Damas, José and Calmy, Alexandra and Haerry, David and Stöckle, Marcel and Schmid, Patrick and Bernasconi, Enos and Fux, Christoph A and Tarr, Philip E and Günthard, Huldrych F and Wandeler, Gilles and Rauch, Andri and Swiss HIV Cohort Study, Swiss HIV Cohort Study},
  title = {Impact of Integrase Inhibitors on Cardiovascular Disease Events in People With Human Immunodeficiency Virus Starting Antiretroviral Therapy},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  volume = {77},
  number = {5},
  pages = {729--737},
  doi = {10.1093/cid/ciad286}
}
Kostenlos starten →